News: Portfolio 2007

TetraLogic Pharmaceuticals Appoints Dr. Andrew Pecora to Its Board of Directors

January 30, 2007: - Malvern, Pa.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals, a privately held company specializing in the discovery and development of oncology therapeutics, announced today that, effective immediately, Dr. Andrew Pecora, FACP, has joined the Company's Board of Directors, bringing the Board to seven members.

 

John M. Gill, President and Chief Executive Officer of TetraLogic Pharmaceuticals, stated, "We are delighted to welcome Dr. Pecora to our Board. He brings to our organization a wealth of expertise in the field of hematology-oncology and cancer research, including clinical trial design, and is a pioneer in the use of Granulocyte Cell Stimulating Factor (GCSF) for the supportive care of cancer patients. Additionally, under his leadership, the Hackensack University Cancer Center, where he is presently Chairman and Executive Administrative Director, has become one of the top cancer centers in the United States. As Founder of two life sciences companies,